1 / 18

Mycoplasma genitalium

Mycoplasma genitalium. Carina Bjartling Dep of Gyn & Obst Skane University Hospital, Malmö, Sweden. Mycoplasmas - class mollicutes. Free-living small bacteria (0.3 - 0.5 μm) Lack a rigid cell wall Commonly found in the human urogenital tract: - M. genitalium 580 bp (1-3%)

mora
Download Presentation

Mycoplasma genitalium

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Mycoplasma genitalium Carina Bjartling Dep of Gyn & Obst Skane University Hospital, Malmö, Sweden

  2. Mycoplasmas-class mollicutes • Free-living small bacteria (0.3 - 0.5 μm) • Lack a rigid cell wall • Commonly found in the human urogenital tract: - M. genitalium 580 bp (1-3%) - M.Hominis 665 bp (20-50%) - Ureaplasma urealyticum 840-950 kbp andU. parvum 751 kbp (40-80%)

  3. Urogenital mycoplasmas Jensen and Unemo. WHO Manual. 2013

  4. Urogenital mycoplasmas • M.hominis, U.urealyticum, U.parvum- commonly detected in healthy individuals • Their association with urogenital infection in either men or women remains to be conclusively proven

  5. Mycoplasma genitalium • Well documented as an agent of NGU in men • Sexually transmitted • Documented as an agent of cervicitis in women • Less well documented in PID • Limited documentation as a patogen in ectopic pregnacy and TFI • Scarse documentation as a patogen in adverse obstetrical outcome

  6. Mycoplasma genitalium • Documented association with HIV and recently a study showing M.genitalium infection to facilitate acquisition of HIV-1 (Mavedzenge SN et al, 2012) • SARA- case reports but no systematic studies

  7. Prevalences of M.genitalium Estimated prevalences in 40 independent studies (27000 women) screened for M.genitalium world wide: - 7.3 % in high-risk population (0 – 42%) - 2.0 % in low-risk population (1- 5 %) - CT (4.2 %) and Ng (0.4 %) (USA) (McGowin et al, 2011) Prevalence in Malmö, Sweden at the women’s clinic emergency service between 2003-2008 in 5519 women -MG- 2.1 % -CT- 2.8 % (Bjartling et al, 2012)

  8. Clinical studies of M.genitalium and PID Case –control studies: Uno et al. 1997, Japan. 2/49 (4%) in cases, 0/80 (0%) in controls Cohen et al. 2002, Kenya, Nairobi. 9/58 (16%) in cases, 1/57 (2%) in controls, endometrial specimen Simms et al. 2003, UK. 6/45 (13%) in cases, 0/37 (0%) in controls Cohen et al. 2005, Kenya, Nairobi. 9/123 (7%), abd. fluid- 1/123 (1%), Haggerty et al. 2006, USA. 7/50 (14%),(8% in endometrial specimen) Bjartling et al. 2012, Sweden. 4/81 (4.9%) in cases, 2/346 (0.6%) in controls Prospective studies: Oakeshott et al, 2010, UK. 3/77 (4%), 12 months follow up Bjartling et al. 2010, Sweden, 6/49 (12%) in cases, 4/168 (2%) in controls, post abortal PID, 6 weeks follow up

  9. Proportions of M.genitalium and C.trachomatis attributable to PID M.genitalium - 4- 16% (5 studies, 1997- 2012) C.trachomatis - 20- 55% (19 studies through the 1990s) - 42% (POPI trial, 2004-2007)

  10. Serological studies of M. genitalium, PID, TFI and ectopic pregnancy – Möller et al, 1984, UK. MG – ab in 40 % of 31 women with PID Lind et al, 1987, Denmark. No ass. between MG – ab and PID in 95 cases of salpingitis Clausen et al, 2001, Denmark, MG- ab in 22 % (29/132) TFI compared to 6.3 % (11/176) of the controls Jurstrand et al, 2007, Sweden, no sign. difference between MG –ab in PID, ectopic pregnancy and normal controls Svenstrup et al, 2008, Denmark. MG – ab in 17 % of 30 TFI cases compared to 4% of the controls Stephen et al, 2006, USA. 2.5 times higher infertility rate among women with MG in the endometrium . Register study 1982-2002

  11. M.genitalium and adverse obstetric outcome • Oakeshott et al 2004, UK, 1216 early pregnant, no ass with miscarriage , MG prevalence 0.7 % • Labbe et al 2002, no sign ass with preterm delivery • Kataoka et al, 2006, no ass for preterm delivery • Edwards et al 2006, USA, Florida. 134 pregnant women, prospective study, preterm delivery, OR 3.48 (1.41- 8.57). • Hitti et al 2010, ass with preterm delivery,OR 2.5 (1.2-5.0)

  12. Diagnosis of M.genitalium • Culture is insensitive and extremely slow • Serologi has low specificity and low sensitivity • NAAT is the only practical method for diagnosis - technically demanding, organism load 100-fold lower than C.trachomatis • No validated (FDA), commercially available assays • Important to validate and quality assure in-house assays • Real- time PCR- robust and lower risk of contamination than PCR

  13. Genital specimen for diagnosis of M.genitalium Summary Men: - FVU (67.0- 97.6%) - Urethral swab (58.0- 82.5%), Women: - self collected vaginal swab (91.0%) - clinician collected cervical swab (58.9- 74.3%) - clinician collected vag swab (57.0- 72.6%) - FVU (61.4- 88.0%) Jensen JS et al, 2004 Wroblevski JK, 2006 Jurstrand M et al, 2005 Edberg A et al 2009 Shipitsyna E, 2009 Lillis RA, 2011 Mobley et al 2012

  14. Treatment of M.genitalium infections • Cure rates of different antibiotics are relatively low and declining • Cure rate azithromycin (1 g azithromycin): • Settings with high usage of azithromycin: 40-85% • Settings with low usage of azithromycin: 95-100%? • Cure rate doxycycline: • 17-45% • Cure rate fluoroquinolones: • Ofloxacin: 50% • Moxifloxacin: 100% Falk, et al. STI. 2003Jernberg, et al. IJSA. 2008Bjørnelius, et al. STI. 2008Mena, et al. CID. 2009Terada, et al. JIC. 2011 Twin, et al. PLoS. 2012Manhart, et al. CID. 2013

  15. Treatment of M.genitalium infections

  16. Treatment of M.genitalium infections First choice: - Azithromycin 500 mg×1 day 1 + 250 mg×1 in the 4 following days (ideally, test-of-cure in ≥14 days) Second choice (if treatment failure and not as first choice!)- Moxifloxacin 400 mg×1 daily in 7 days Jensen, personal communication, July 2013

  17. Take home messages • The estimated proportion of M.genitalium and C.trachomatis attributable to PID is about 2-16% and 20-55% respectively • Focus on detection and treatment of M.genitalium (not M.Hominis or Ureaplasma spp) • Important to validate and quality assure in-house assays • No clear guidance can be given in the choice of optimal genital specimen but FVU in men and self collected vaginal specimen in women seems to have the highest bacterial load • Cure rates of different antibiotics are relatively low and antimicrobial resistance and treatment failure in M.genitalium infections are common • First choice for treament of M.genitalium infection is Azithromycin 500 mg×1 day 1 + 250 mg×1 in the 4 following days

  18. Thank you

More Related